Retension Pharmaceuticals Inc.
RTSNHealthcare|Medical - Pharmaceuticals|US
$11.04
+0.32 (+2.99%)
About
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Stock Price
+4.8%(1Y)
1M
+4.8%
3M
+4.8%
6M
+4.8%
YTD
+4.8%
1Y
+4.8%
3Y
+4.8%
5Y
+4.8%
Pipeline Summary
3 total trials0
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Completed: 2Recruiting: 1
Active Trials (1)
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
NCT07142356Uncontrolled Hypertension
Phase 2Recruiting
Enrollment: 280 participants
Key Facts
Market Cap$41.4M
Employees12
CEOEric L. Keller
IPO DateOct 9, 2026
Beta0.00
52-Week Range$9.66 – $18.64
Avg Volume140,058
ExchangeNASDAQ
Websiteretensionpharmaceuticals.com
Ownership
Shares Outstanding3.8M
Recent Insider Trades
Wong RobertAWARD
Nov 2, 202625,000 shares @ $11.30
Wong RobertOTHER
Nov 2, 20260 shares
Keller Eric L.AWARD
Oct 22, 202640,884 shares @ $15.50
B Group, Inc.OTHER
Oct 13, 20260 shares
Keller Eric L.CONVERSION
Oct 13, 202631,368 shares
Recent News
Retension Pharmaceuticals to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 5, 2026 · globenewswire.com
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
Oct 8, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:32 AM